*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# Zylox-Tonbridge Medical Technology Co., Ltd.
# 歸創通橋醫療科技股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2190)**

## VOLUNTARY ANNOUNCEMENT
## INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the "**Company**") on a voluntary basis.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company decided to continue H share repurchase plan and resolved to adjust the maximum amount for the repurchase of H share of the Company (the "**H Shares**") to an amount not exceeding HKD650 million given the continous increase in the price of H Shares.

The Board further announces that, following the expiration of the repurchase mandate as approved at the 2023 annual general meeting of the Company held on June 6, 2024 and subject to the approval of a new repurchase mandate at the forthcoming 2024 annual general meeting of the Company (the "**New Repurchase Mandate**"), the Company decided to continue to repurchase H Shares in the open market from time to time under the New Repurchase Mandate. The implementation of such repurchase is subject to foreign exchange remittance approval with the relevant regulatory authorities in the People's Republic of China (the "**PRC**") in relation to share repurchases.

The Company believes that a share repurchase in the present conditions will demonstrate the Company's confidence in its own business outlook and prospects and would, ultimately, benefit the Company and create value to its shareholders. The Board believes that the current financial resources of the Company would enable it to implement the share repurchase while maintaining a solid financial position.

**Shareholders of the Company and potential investors should note that the implementation of the on-market share repurchase by the Company will be subject to market conditions and will be at the absolute discretion of the Board and/or its authorized person(s). There is no assurance of the timing, quantity or price of any repurchases or whether the Company will make any repurchases at all. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board
**Zylox-Tonbridge Medical Technology Co., Ltd.**
**Dr. Jonathon Zhong Zhao**
*Chairman and Executive Director*

Hong Kong, April 25, 2025

*As at the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Ms. Yun Qiu and Dr. Xiang Qian as independent non-executive Directors.*